Clinical Trial Update: ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing ELB245 to tolterodine in patients with incontinent overactive bladder was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• ELB245
• Tolterodine (tolterodine)

Snippet

Sponsor: elbion AG | Conditions: Overactive Bladder, Urinary Incontinence | Phase 2 | Status: TERMINATED